Chloroquine reduces whole body proteolysis in humans

P. De Feo, Elena Volpi, P. Lucidi, G. Cruciani, F. Santeusanio, G. B. Bolli, P. Brunetti

Research output: Contribution to journalArticle

Abstract

The antimalaric drug chloroquine is a well known inhibitor of lysosomal proteolysis in vitro. The present study tests the hypothesis that therapeutic doses of the drug decrease proteolysis also in vivo in humans. Leucine kinetics were determined in 20 healthy volunteers given 12 and 1.5 h before the studies 250 and 500 mg, respectively, of chloroquine phosphate (n = 10) or similar tablets of placebo (n = 10). Chloroquine reduced the rates of leucine appearance, a measure of whole body proteolysis, from 2.45 ± 0.08 to 2.19 ± 0.08 μmol · kg-1 · min-1 (P = 0.038) and those of nonoxidative leucine disposal, an estimate of whole body protein synthesis, from 2.16 ± 0.08 to 1.95 ± 0.06 μmol · kg-1 · min-1 (P = 0.050). The drug resulted also in a marginally significant (P = 0.051) decrement in the plasma concentrations of glucose. The effects of chloroquine on protein turnover might be potentially useful in counteracting protein wasting complicating several catabolic diseases, whereas those on glucose metabolism can explain the sporadic occurrence of severe hypoglycemic episodes in malaria patients chronically treated with this drug.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume267
Issue number1 30-1
StatePublished - 1994
Externally publishedYes

Fingerprint

Proteolysis
Chloroquine
Leucine
Pharmaceutical Preparations
Body Weights and Measures
Glucose
Enzyme kinetics
Proteins
Hypoglycemic Agents
Metabolism
Tablets
Malaria
Healthy Volunteers
Placebos
Plasmas

Keywords

  • α-ketoisocaproate
  • leucine kinetics
  • malaria
  • protein catabolism
  • rheumathoid arthritis

ASJC Scopus subject areas

  • Physiology
  • Endocrinology
  • Biochemistry

Cite this

De Feo, P., Volpi, E., Lucidi, P., Cruciani, G., Santeusanio, F., Bolli, G. B., & Brunetti, P. (1994). Chloroquine reduces whole body proteolysis in humans. American Journal of Physiology - Endocrinology and Metabolism, 267(1 30-1).

Chloroquine reduces whole body proteolysis in humans. / De Feo, P.; Volpi, Elena; Lucidi, P.; Cruciani, G.; Santeusanio, F.; Bolli, G. B.; Brunetti, P.

In: American Journal of Physiology - Endocrinology and Metabolism, Vol. 267, No. 1 30-1, 1994.

Research output: Contribution to journalArticle

De Feo, P, Volpi, E, Lucidi, P, Cruciani, G, Santeusanio, F, Bolli, GB & Brunetti, P 1994, 'Chloroquine reduces whole body proteolysis in humans', American Journal of Physiology - Endocrinology and Metabolism, vol. 267, no. 1 30-1.
De Feo P, Volpi E, Lucidi P, Cruciani G, Santeusanio F, Bolli GB et al. Chloroquine reduces whole body proteolysis in humans. American Journal of Physiology - Endocrinology and Metabolism. 1994;267(1 30-1).
De Feo, P. ; Volpi, Elena ; Lucidi, P. ; Cruciani, G. ; Santeusanio, F. ; Bolli, G. B. ; Brunetti, P. / Chloroquine reduces whole body proteolysis in humans. In: American Journal of Physiology - Endocrinology and Metabolism. 1994 ; Vol. 267, No. 1 30-1.
@article{364f3da5237a40b48caa4b94a74655b6,
title = "Chloroquine reduces whole body proteolysis in humans",
abstract = "The antimalaric drug chloroquine is a well known inhibitor of lysosomal proteolysis in vitro. The present study tests the hypothesis that therapeutic doses of the drug decrease proteolysis also in vivo in humans. Leucine kinetics were determined in 20 healthy volunteers given 12 and 1.5 h before the studies 250 and 500 mg, respectively, of chloroquine phosphate (n = 10) or similar tablets of placebo (n = 10). Chloroquine reduced the rates of leucine appearance, a measure of whole body proteolysis, from 2.45 ± 0.08 to 2.19 ± 0.08 μmol · kg-1 · min-1 (P = 0.038) and those of nonoxidative leucine disposal, an estimate of whole body protein synthesis, from 2.16 ± 0.08 to 1.95 ± 0.06 μmol · kg-1 · min-1 (P = 0.050). The drug resulted also in a marginally significant (P = 0.051) decrement in the plasma concentrations of glucose. The effects of chloroquine on protein turnover might be potentially useful in counteracting protein wasting complicating several catabolic diseases, whereas those on glucose metabolism can explain the sporadic occurrence of severe hypoglycemic episodes in malaria patients chronically treated with this drug.",
keywords = "α-ketoisocaproate, leucine kinetics, malaria, protein catabolism, rheumathoid arthritis",
author = "{De Feo}, P. and Elena Volpi and P. Lucidi and G. Cruciani and F. Santeusanio and Bolli, {G. B.} and P. Brunetti",
year = "1994",
language = "English (US)",
volume = "267",
journal = "American Journal of Physiology - Endocrinology and Metabolism",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "1 30-1",

}

TY - JOUR

T1 - Chloroquine reduces whole body proteolysis in humans

AU - De Feo, P.

AU - Volpi, Elena

AU - Lucidi, P.

AU - Cruciani, G.

AU - Santeusanio, F.

AU - Bolli, G. B.

AU - Brunetti, P.

PY - 1994

Y1 - 1994

N2 - The antimalaric drug chloroquine is a well known inhibitor of lysosomal proteolysis in vitro. The present study tests the hypothesis that therapeutic doses of the drug decrease proteolysis also in vivo in humans. Leucine kinetics were determined in 20 healthy volunteers given 12 and 1.5 h before the studies 250 and 500 mg, respectively, of chloroquine phosphate (n = 10) or similar tablets of placebo (n = 10). Chloroquine reduced the rates of leucine appearance, a measure of whole body proteolysis, from 2.45 ± 0.08 to 2.19 ± 0.08 μmol · kg-1 · min-1 (P = 0.038) and those of nonoxidative leucine disposal, an estimate of whole body protein synthesis, from 2.16 ± 0.08 to 1.95 ± 0.06 μmol · kg-1 · min-1 (P = 0.050). The drug resulted also in a marginally significant (P = 0.051) decrement in the plasma concentrations of glucose. The effects of chloroquine on protein turnover might be potentially useful in counteracting protein wasting complicating several catabolic diseases, whereas those on glucose metabolism can explain the sporadic occurrence of severe hypoglycemic episodes in malaria patients chronically treated with this drug.

AB - The antimalaric drug chloroquine is a well known inhibitor of lysosomal proteolysis in vitro. The present study tests the hypothesis that therapeutic doses of the drug decrease proteolysis also in vivo in humans. Leucine kinetics were determined in 20 healthy volunteers given 12 and 1.5 h before the studies 250 and 500 mg, respectively, of chloroquine phosphate (n = 10) or similar tablets of placebo (n = 10). Chloroquine reduced the rates of leucine appearance, a measure of whole body proteolysis, from 2.45 ± 0.08 to 2.19 ± 0.08 μmol · kg-1 · min-1 (P = 0.038) and those of nonoxidative leucine disposal, an estimate of whole body protein synthesis, from 2.16 ± 0.08 to 1.95 ± 0.06 μmol · kg-1 · min-1 (P = 0.050). The drug resulted also in a marginally significant (P = 0.051) decrement in the plasma concentrations of glucose. The effects of chloroquine on protein turnover might be potentially useful in counteracting protein wasting complicating several catabolic diseases, whereas those on glucose metabolism can explain the sporadic occurrence of severe hypoglycemic episodes in malaria patients chronically treated with this drug.

KW - α-ketoisocaproate

KW - leucine kinetics

KW - malaria

KW - protein catabolism

KW - rheumathoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0028359181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028359181&partnerID=8YFLogxK

M3 - Article

C2 - 8048508

VL - 267

JO - American Journal of Physiology - Endocrinology and Metabolism

JF - American Journal of Physiology - Endocrinology and Metabolism

SN - 0193-1849

IS - 1 30-1

ER -